Background Pemetrexed plus cisplatin was approved for first-line treatment of non–small-
cell lung cancer (NSCLC) in patients with nonsquamous histology after initiation of this …

Background Subgroup analyses of randomized studies have consistently shown that
pemetrexed is exclusively effective in non-small-cell lung cancer (NSCLC) other than …

Background The objective of this study was to evaluate the efficacy and safety of
pemetrexed plus cisplatin/carboplatin in locally advanced or metastatic non-small cell lung …

Purpose: To determine efficacy and toxicity of two pemetrexed-based regimens in
chemonaive patients with locally advanced or metastatic non–small cell lung cancer …

Purpose To compare efficacy of pemetrexed versus pemetrexed plus carboplatin in
pretreated patients with advanced non–small-cell lung cancer (NSCLC). Patients and …

BACKGROUND The primary objectives of this study were to determine the efficacy and
tolerability of a pemetrexed‐carboplatin combination as first‐line therapy in patients with …

Introduction Recent phase III studies in advanced non–small-cell lung cancer (NSCLC) have
demonstrated differential efficacy for pemetrexed according to NSCLC histology. The results …

Introduction: For patients with advanced NSCLC, treatment outcomes are still disappointing
and the search for new active and safe drugs is warranted. The chemotherapeutic agent …

Background The main objective of this study was to evaluate the safety of second-line
pemetrexed in Stage IIIB or IV NSCLC. Methods Overall, 95 patients received pemetrexed …

Objectives Two phase III trials of advanced NSCLC patients were compared to examine
relative efficacy and safety of differing treatment regimens. The JMDB trial investigated first …